* Editas Medicine Inc reported a quarterly adjusted loss of 75 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -55 cents. The mean expectation of eighteen analysts for the quarter was for a loss of 75 cents per share. Wall Street expected results to range from -96 cents to -13 cents per share.

* Revenue fell 98.9% to $61.00 thousand from a year ago; analysts expected $2.24 million.

* Editas Medicine Inc's reported EPS for the quarter was a loss of 75 cents​.

* The company reported a quarterly loss of $62.14 million.

* Editas Medicine Inc shares had fallen by 14.7% this quarter and lost 71.3% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had fallen by about 7.5% in the last three months.​

* In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 9 "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Editas Medicine Inc is $10.00 This summary was machine generated from LSEG data November 4 at 03:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.75 -0.75 Met

Jun. 30 2024 -0.70 -0.82 Missed

Mar. 31 2024 -0.66 -0.76 Missed

Dec. 31 2023 -0.54 -0.23 Beat